Oxford Biomedica PLC Notice of Preliminary Results (0856Z)
March 10 2017 - 2:01AM
UK Regulatory
TIDMOXB
RNS Number : 0856Z
Oxford Biomedica PLC
10 March 2017
Oxford BioMedica: Notice of Preliminary Results
Results date: 16 March 2017
Oxford, UK - 10 March 2017: Oxford BioMedica plc (LSE: OXB)
("OXB" or "the Group"), a leading gene and cell therapy group, will
be announcing its preliminary results for the twelve months ended
31 December 2016 on Thursday 16 March 2017.
A briefing for analysts will be held at 09:30 GMT on 16 March
2017 at 85 Gresham Street, London, EC2V 7NQ. There will be a
simultaneous live conference call with Q&A and the presentation
will be available on the Group's website at
www.oxfordbiomedica.co.uk. An audio replay file will be made
available shortly afterwards.
Please contact Consilium Strategic Communications for further
details.
For further information, please contact:
Oxford BioMedica plc: Tel: +44 (0)1865 783 000
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Financial PR Enquiries: Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Matthew Neal / Chris Welsh / Laura
Thornton
Consilium Strategic Communications
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, Orchard
Therapeutics and Immune Design, through which it has long-term
economic interests in other potential gene and cell therapy
products. Oxford BioMedica is based across several locations in
Oxfordshire, UK and employs more than 250 people. Further
information is available at www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOREAFDNESXXEAF
(END) Dow Jones Newswires
March 10, 2017 02:01 ET (07:01 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024